Sells it 17%, $6.2B a year“BLINCYTO was launched in 2014 and has proven efficacy in a wide range of patients with CD19-positive B-cell acute lymphoblastic leukemia (B-ALL), including those who are MRD(–) or MRD(+) in frontline consolidation, and those with relapsed or refractory (R/R) disease.”
Latest 10-KFY2025Impairment / charge ·
Repatha and TEZSPIRE growth outweighed ENBREL’s price-led decline; Prolia and XGEVA biosimilars threaten faster erosion.
Revenue$36.8BYoY +10.0%
Net income$7.7BYoY +88.5%
Latest 10-QQ3 FY2026 ·
Repatha, UPLIZNA and IMDELLTRA demand more than offsets biosimilar erosion in Prolia and XGEVA.
Revenue$10.4BYoY +8.5%
Net income$3.9BYoY +20.1%
Latest 8-KPositiveEarningsGuidance raised ·
Repatha and IMDELLTRA sales surge as biosimilars hit Prolia and XGEVA; FY2026 revenue outlook rises to $38.9B–$39.7B.
Latest 8-KLeadership change ·
Former Yum! Brands CEO David Gibbs joins the board, bringing direct customer relationship experience to inform future product launches
Latest 8-KCybersecurity incident ·
Third-party cloud data theft deemed material due to file volume and potential sensitivity, including proprietary and patient health information
Latest 8-KShareholder vote ·
Shareholders rejected a requirement for an independent board chairman and elected all director nominees.
Latest 8-KCEO/CFO change ·
Thomas Dittrich returns from Galderma to succeed retiring CFO Peter Griffith, who stays through January 2027 to support the transition.
Latest 8-KDebt financing ·
Issues senior unsecured notes across four tranches, with maturities extending to 2056.
In development“We are a clinical-stage biopharmaceutical company applying our intentional, chemistry-based approach to develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment.”
Sells it 48%, $22.9B a year“It has been approved for several anti-cancer indications including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer.”
Latest 10-KFY2025MixedImpairment / charge ·
Reblozyl, Breyanzi and Camzyos gains offset Revlimid erosion; lower acquisition charges drove the GAAP earnings rebound.
Revenue$48.2BYoY −0.2%
Net income$7.1Bvs −$8.9B year ago
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis drove growth as generics eroded Revlimid and Pomalyst; pipeline licensing charges weighed on earnings.
Weak BioSpin and NANO demand, tariffs and impairments overwhelmed CALID growth; Bruker is restructuring to restore margins.
Revenue$3.4BYoY +2.1%
Net income−$8.6Mvs $113.1M year ago
Latest 10-QQ3 FY2026Impairment / charge ·
Competition and weak BSB&CA performance erase its remaining goodwill, while cost savings and product mix lift margins.
Revenue$874.0MYoY +1.6%
Net income−$111.8MYoY −87.6%
Latest 8-KLeadership change ·
Board adds immunologist Eicke Latz as life-science work expands; declares $0.05/share quarterly dividend.
Latest 8-KInvestor update ·
BioSpin and CALID divisions reorganized into BIOS and new BMID to sharpen accountability; historical segment results recast without changing consolidated results.
In development“We are conducting a Phase 1 clinical trial evaluating ipsoprubart as a monotherapy in patients with relapsed/refractory T cell and natural killer (NK) cell malignancies, with initial data expected in the second half of 2027.”
In development“Additionally, we are engaged in a number of discovery stage programs in indications, including oncology, metabolic disease and endocrinology, which we estimate represent an over $70 billion in aggregate global commercial opportunity.”
Supplies it“Radical prostatectomy is the removal of the prostate gland in patients diagnosed with clinically localized prostate cancer.”
Latest 10-KFY2025 ·
Intuitive Surgical delivered broad-based FY2025 growth as rising procedure volumes expanded recurring revenue and da Vinci 5 accelerated system placements. Revenue increased 21% and operating income increased 25%, despite lower gross margins from tariffs, new-system costs, manufacturing expansion, and service repairs. The investment case rests on converting a larger installed base into sustained…
da Vinci antitrust settlement drives a $450M charge and GAAP profit decline despite procedure and lease growth
Latest 8-KGovernance change ·
Bylaws tighten shareholder nomination and proxy rules; non-director-election actions shift to majority of votes cast, excluding abstentions and broker non-votes.
Latest 8-KBuybackExecutive payShareholder vote ·
Board expands buyback authorization to $5.0B; stockholders extend the incentive plan and increase its share reserve.
Latest 8-KPositiveDeal completed ·
Acquisition of da Vinci and Ion distributors expands direct operations in Italy, Spain and Portugal.
Sells it 14%, $9.4B a year“For use as monotherapy or in combination with endocrine therapy for the treatment of HR+, HER2- metastatic breast cancer, and in combination with endocrine therapy for treatment of HR+, HER2-, node positive, early breast cancer at high risk of recurrence.”
Latest 10-KFY2025PositiveImpairment / charge ·
Mounjaro and Zepbound volume drove growth despite lower realized U.S. prices; Lilly is expanding manufacturing capacity.
Revenue$65.2BYoY +44.7%
Net income$20.6BYoY +94.9%
Latest 10-QQ3 FY2026PositiveImpairment / charge ·
Mounjaro and Zepbound volume growth outweighed lower prices, while acquired research charges constrained profit growth.
Sells it“Oncology & Multispecialty growth reflected specialty pharmaceutical sales and provider solutions, partly offset by higher costs and the absence of a prior-year $51 million investment-sale/market-decision gain.”
Latest 10-QQ2 FY2027Restructuring ·
Precision Medicine Group and Spectrum Vision acquisitions expand specialty care as separation costs squeeze Medical-Surgical profit.
Revenue$111.0BYoY +7.6%
Net income$1.2BYoY +9.7%
Latest 8-KPositiveEarningsGuidance raised ·
Prescription volumes and specialty distribution drive growth as FY2027 adjusted EPS outlook rises; CVS Health partnership extended through June 2032.
Sells it 54%, $34.9B a year“approved as monotherapy for the treatment of certain patients with cervical cancer, classical Hodgkin lymphoma (cHL), cutaneous squamous cell carcinoma, esophageal or gastroesophageal junction (GEJ) carcinoma, head and neck squamous cell carcinoma (HNSCC), hepatocellular carcinoma (HCC), melanoma, Merkel cell carcinoma, microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) solid tumors (including MSI-H/dMMR colorectal cancer and endometrial carcinoma), non-small cell lung cancer (NSCLC), primary mediastinal large B-cell lymphoma (PMBCL), tumor mutational burden-high (TMB-H) solid tumors, and urothelial cancer including non-muscle invasive bladder cancer.”
Latest 10-KFY2025Restructuring ·
China Gardasil inventory overhang blunted Keytruda and Winrevair growth; launches and acquisitions seek replacement revenue.
Revenue$65.0BYoY +1.3%
Net income$18.3BYoY +6.6%
Latest 10-QQ3 FY2026Impairment / charge ·
Keytruda Qlex offsets IV declines; purchase timing lifts sales as pipeline acquisitions weigh on earnings.
Revenue$18.1BYoY +4.7%
Net income$5.1BYoY −12.4%
Latest 8-KLeadership change ·
Douglas M. Baker Jr. succeeds Thomas H. Glocer as independent lead director Jan. 1, 2027, ahead of Glocer’s May 2027 board retirement.
In development“In Phase 3 INTerpath-001 melanoma, intismeran autogene plus Merck’s KEYTRUDA reduced recurrence or death risk by 42% (HR 0.58; 95% CI 0.45–0.75; p<0.001) and distant-metastasis or death risk by 38% (HR 0.62; 95% CI 0.45–0.85; p=0.002) after median follow-up of 24.6 months.”
European COVID deliveries and lower R&D spending restored quarterly profit; mFLUSIVA launched after the main contracting season.
Revenue$1.3BYoY +29.2%
Net income$162.0Mvs −$200.0M year ago
Latest 8-KPositiveDebt financing ·
Credit amendment cuts initial and delayed-draw term-loan margins 75 bp and extends maturity to November 2031.
Latest 8-KLeadership change ·
Chief Legal Officer Klinger to retire March 2027 with $1.63M severance and conditional payouts tied to Arbutus/Genevant and Pfizer/BioNTech litigation.
Sells it 60%, $494.1M a year“In oncology, we offer testing for patients across their cancer journey, from identification of genes that increase cancer risk, to predicting whether they are candidates for targeted treatments.”
In development“NanO2 is being developed as a radiation therapy sensitizer providing an oxygen supplement to facilitate oxygen free radical generation.”
Sells it“Innovative oncology product portfolio of ADCs, small molecules, bispecifics and other immunotherapies that treat a wide range of cancers including certain types of breast cancer, genitourinary cancer and hematologic malignancies, as well as certain types of melanoma, gastrointestinal, gynecological and lung cancer – select products include: Ibrance, Xtandi, Padcev, Adcetris, Inlyta, Lorbrena, Bosulif, Tukysa, Braftovi, Mektovi, Orgovyx, Elrexfio, Tivdak and Talzenna.”
Latest 10-KFY2025Impairment / charge ·
Paxlovid and Comirnaty declines masked non-COVID growth; the Metsera deal targets obesity as patent losses loom.
Revenue$62.6BYoY −1.6%
Net income$7.8BYoY −3.2%
Latest 10-QQ3 FY2026MixedImpairment / charge ·
Eliquis and Padcev gains counter COVID-19 declines, but pipeline write-downs expose risks in replacing aging franchises.
Revenue$16.6BYoY −0.4%
Net income$3.2BYoY −8.4%
Latest 8-KCEO/CFO change ·
Interim CFO Cecile Guegan appointed permanent CFO and EVP, effective Nov. 1.
Expanded Sanofi pact covers four long-acting antibodies with $1.0B upfront and up to $7.0B in milestones, and settles information-access lawsuit.
Latest 8-KExecutive pay ·
10-year CEO and chief scientific officer equity awards replace annual grants through 2036, tying payouts to new-product revenue and pipeline milestones.
Supplies it“We have entered into drug discovery collaborations with biopharmaceutical companies under which our collaborators are pursuing research in a number of therapeutic areas, including programs in oncology, antifungal diseases, fibrosis, inflammatory bowel disease, metabolic disease, autoimmune disease, immuno-oncology, cardiopulmonary disease, CNS diseases, and tuberculosis.”
Latest 10-KFY2025MixedRestructuring ·
Novartis collaboration work and hosted-software sales drove growth, but higher delivery costs squeezed gross margin.
In development“We are a clinical-stage biotechnology company focused on improving standard-of-care therapies for people with cancer through application of our proprietary platform of delivery technology systems.”
Supplies it“This covers liquid biopsy for therapy selection, multicancer screening (multicancer early detection and multicancer detection) and molecular residual disease (MRD), plus comprehensive genomic profiling (CGP) of tissue;”
Latest 10-KFY2026Positive ·
AI-enabled drug discovery lifts DNA Synthesis and Protein Solutions, but commercial hiring and litigation absorb gross-profit gains.
Revenue$459.4MYoY +22.0%
Net income−$130.2MYoY −67.6%
Latest 10-QQ3 FY2026Legal / investigation ·
Synthetic biology and therapeutics demand drove growth, but commercial and infrastructure spending widened operating losses.